The basic leucine zipper transcription factor CCAAT͞enhancer binding protein-␤ (C͞EBP␤) is expressed in many cell types, including keratinocytes. C͞EBP␤ activity can be increased by phosphorylation through pathways stimulated by oncogenic Ras, although the biological implications of Ras-C͞EBP␤ signaling are not currently understood. We report here that C͞EBP␤-nullizygous mice are completely refractory to skin tumor development induced by a variety of carcinogens and carcinogenesis protocols, including 7,12-dimethylbenz-[a]anthracene-initiation͞12-O-tetradecanoylphorbol 13-acetate promotion, that produce tumors containing oncogenic Ras mutations. No significant differences in TPA-induced epidermal keratinocyte proliferation were observed in C͞EBP␤-null versus wild-type mice. However, apoptosis was significantly elevated (17-fold) in the epidermal keratinocytes of 7,12-dimethylbenz[a]anthracene-treated C͞EBP␤-null mice compared with wild-type mice. In v-Ha-ras transgenic mice, C͞EBP␤ deficiency also led to greatly reduced skin tumor multiplicity and size, providing additional evidence for a tumorigenesis pathway linking Ras and C͞EBP␤. Oncogenic Ras potently stimulated C͞EBP␤ to activate a C͞EBP-responsive promoter-reporter in keratinocytes and mutating an ERK1͞2 phosphorylation site (T188) in C͞EBP␤ abolished this Ras effect. Finally, we observed that C͞EBP␤ participates in oncogenic Ras-induced transformation of NIH 3T3 cells. These findings indicate that C͞EBP␤ has a critical role in Ras-mediated tumorigenesis and cell survival and implicate C͞EBP␤ as a target for tumor inhibition.
T
he Ras family of GTP binding proteins function as intracellular mediators of extracellular signals to regulate cell proliferation, apoptosis, survival, senescence, and differentiation (1) (2) (3) (4) (5) . Ras protooncogenes are frequently mutated in tumors, and Ϸ25% of human cancers contain transforming mutations in ras. Therefore, understanding oncogenic Ras-signaling pathways is critical for elucidating the mechanisms that underlie cellular transformation and for designing effective therapeutic strategies to prevent the development or block the growth of many classes of tumors. Ras has numerous effectors, and its pathways are multifaceted (3, 6, 7) . Ras activation by growth factors or oncogenic mutations elicits activation of several transcription factors, which in turn regulate the expression of genes that control the cellular responses to Ras signaling, including oncogenesis. The transcription factors Ets, c-jun, c-myc, and NF-B are known to have roles in oncogenic ras-induced cellular transformation (8) (9) (10) (11) .
The basic leucine zipper (bZIP) transcription factor CCAAT͞ enhancer binding protein-␤ (C͞EBP␤, also known as NF-IL6, IL-6DBP, LAP, CRP2, and NF-M) is expressed in a variety of cell types (12, 13) including keratinocytes (14, 15) , where it plays a role in squamous differentiation (16) . C͞EBP␤ is also involved in regulating differentiation of specific mesenchymal, epithelial, and hematopoietic cell types (17) (18) (19) (20) (21) . C͞EBP␤ activity can be activated or derepressed by phosphorylation through pathways stimulated by oncogenic Ras in fibroblasts, erythoblasts, and P19 embryonal carcinoma cells (22, 23) , suggesting a role for C͞EBP␤ as a nuclear effector of Ras signaling. However, the physiological functions of C͞EBP␤ as a downstrean target of Ras are unclear.
The fact that C͞EBP␤ is present in numerous epithelial and hematopoietic cells, and that some of these cell types give rise to human and rodent tumors containing mutant Ras (24, 25) , prompted us to investigate whether C͞EBP␤ has a role in oncogenic Ras-mediated tumorigenesis and transformation. To address this question, we have examined C͞EBP␤-nullizygous mice in the mouse skin model of multistage carcinogenesis. The mouse skin model is one of the best-defined in vivo paradigms of experimental epithelial carcinogenesis (26, 27) , and there is ample evidence that the mutational activation of Ras plays a central role in skin tumor development induced by a variety of carcinogens (25, (27) (28) (29) . For example, initiation with a single dose of the carcinogen 7,12-dimethylbenz[a]anthracene (DMBA), followed by repetitive treatment with the tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA), results in the appearance of squamous papillomas, 95-100% of which contain an A 3 T 182 mutation in Ha-ras (25, 28, 29) . Furthermore, transgenic mice that express an oncogenic Ras transgene in their epidermis develop skin tumors, demonstrating a causal role for activated Ras in squamous papilloma development (30, 31) .
Here we report that C͞EBP␤-null mice are completely refractory to carcinogen-induced skin tumors involving mutant Ras and that v-Ha-ras transgenic mice that carry the C͞EBP␤-null mutation also show a significant reduction in tumorigenesis. Apoptosis was significantly elevated in C͞EBP␤-null mice in response to DMBA but not to ultraviolet-B (UVB) treatment. These findings reveal a previously uncharacterized role for C͞EBP␤ in tumorigenesis and cell survival.
Methods
Tumor Experiments in Wild-Type and C͞EBP␤ Mutant Mice. The C͞EBP␤-deficient mice used in our studies have been described (32) . The mutant and wild-type mice were generated by mating heterozygous 129͞Sv females to heterozygous males from the sixthto eighth-generation backcross into the C57BL͞6 strain. No significant sex difference in tumor response was observed.
QuickChange system (Stratagene). BALB͞MK2 keratinocytes (a gift from B. E. Weissman, Univ. North Carolina, Chapel Hill) at Ϸ25-30% confluence were transfected by using Lipofectin reagent (GIBCO͞BRL) with pcDNA3-C͞EBP␤ (0.5 g) and͞or pcDNA3-Ha-ras(12V) (0.5 g) (gift from C. J. Der, Univ. North Carolina) and 1.0 g of the specified C͞EBP-dependent promoter͞reporter as described in the text. The total amount of DNA among all groups was kept constant by using empty vector. After 4 h, cultures were washed and grown in low-calcium Eagle's minimal essential medium containing 4 ng/ml epidermal growth factor, 0.05 mM calcium chloride, and 8% chelex treated FBS. Forty-eight hours later, cells were harvested and luciferase activity was determined (16) . Primary keratinocytes were isolated from C͞EBP␤ Ϫ/Ϫ or C͞EBP␤ ϩ/ϩ newborn littermates (2-3 days old) and cultured as described (14, 16) . At Ϸ100% confluence, cells were transfected by using the PerFect Lipid, Pfx-3 (Invitrogen). Cells were processed for reporter assays as described above.
Detection of Apoptotic Cells. Wild-type and C͞EBP␤-null mice were treated with a single dose of 400 nmol DMBA, and 24 h later the treated dorsal skin was excised and fixed for 24 h in a 10% neutral buffered formalin, processed, and embedded in paraffin. Hematoxylin and eosin-stained sections (5 m) were examined. Apoptotic keratinocytes in the stratum basale were scored by using the following criteria: dark pyknotic nuclei, cytoplasmic eosinophilia, and absence of cellular contacts.
NIH 3T3 Cell Focus Assay. NIH 3T3 cells (gift from C. J. Der) were plated at 5 ϫ 10 5 cells per 60-mm dish in DMEM containing 10% calf serum. One day later the cells were transfected by using a calcium phosphate precipitation method (33) . Transformed foci were identified 14 days after transfection as defined by Clark et al. (33) .
Western Analysis. BALB͞MK2 keratinocytes were transfected with pcDNA3-C͞EBP␤ (0.5 g) and͞or pcDNA3-Ha-ras(12V) (0.5 g) as described above. Forty-eight hours later, lysates were prepared, equal amounts of each protein sample were loaded on 10% polyacrylamide Tris⅐glycine gels (Novex) and separated by electrophoresis, and Western analysis was conducted with a rabbit polyclonal IgG raised against C͞EBP␤ or Ras (1:2,000; Santa Cruz Biotechnology).
Tg.AC ؋ C͞EBP␤ ؊/؊ Crosses. Female Tg.AC mice (R. Cannon, National Institute on Environmental Health Sciences, RTP, NC) were crossed with C͞EBP␤ Ϫ/Ϫ mice, and F 1 mice were backcrossed to C͞EBP␤ Ϫ/ϩ mice. Mice were genotyped by Southern analysis for v-Ha-ras and C͞EBP␤. All v-Ha-ras-positive mice were also genotyped to verify that they were of the responder genotype (34) .
Results
Effect of C͞EBP␤ Deficiency on Skin Tumor Development. Initiation with a single dose of DMBA followed by TPA treatment produces squamous papillomas, 95-100% of which contain an A 3 T (182) mutation in Ha-ras (25, 28, 29) . Therefore, C͞EBP␤ nullizygous and wild-type littermates were initiated with 200 nmol DMBA, and 1 week later these mice were promoted thrice weekly with 5 nmol TPA for 25 weeks. Wild-type mice developed an average of 15 squamous papillomas per mouse and exhibited a 100% incidence of papillomas ( Fig. 1 a and b) . In contrast, C͞EBP␤ nullizygous mice were completely refractory to papilloma development and no papillomas appeared after 25 weeks of promotion. In some groups of mutant mice, TPA promotion was continued for 35 weeks, but no tumors developed within this time (data not shown). C͞EBP␤ heterozygous mice express a level of C͞EBP␤ protein in keratinocytes that is intermediate between that of wild-type and C͞EBP␤-deficient animals (14) . C͞EBP␤ heterozygous mice were partially resistant to DMBA͞TPA-induced carcinogenesis ( Fig. 1 a and b) , indicating that the tumor-modifying effect of C͞EBP␤ is genedosage dependent.
Because C͞EBP␤ can be phosphorylated via a protein kinase C pathway (35) , and because this event is required for TPA-induced mitogenesis in hepatocytes (36), we examined whether TPAinduced keratinocyte proliferation was altered in epidermis of C͞EBP␤-null mice. No significant differences were observed between wild-type and C͞EBP␤ nullizygous mice after single or multiple treatment with TPA (Table 1) . C͞EBP␤ has been implicated in the regulation of cyclooxygenase 2 (COX2; ref. 37 ) and tumor necrosis factor (TNF-␣) (38) expression and both TNF-␣-null (39) and COX2-null (40) mice are partially resistant to DMBA͞ TPA-induced carcinogenesis. However, TNF-␣ mRNA and COX2 protein expression were not different in untreated or TPA-treated C͞EBP␤-deficient mice compared with similarly treated wild-type mice (data not shown). These results indicate that TNF-␣ and COX2 expression, as well as TPA-induced proliferative responses in the epidermis of C͞EBP␤-null mice, are normal and thus are not responsible for the resistance of C͞EBP␤-null mice to DMBA͞ TPA-induced tumorigenesis.
To test the possibility that C͞EBP␤ nullizygous mice are refractory to DMBA initiation because of their inability to convert DMBA to the carcinogenic species, we subjected the mice to the direct-acting carcinogen N-methyl-NЈ-nitro-N-nitrosoguanidine (MNNG) followed by TPA promotion. The MNNG͞TPA carcinogenesis protocol produces papillomas, 85-90% of which contain oncogenic mutations in the 12th codon of either Ha-ras (25, 41) or Ki-ras (41) . Wild-type mice displayed a 100% incidence of papillomas with Ϸ3 papillomas per mouse, whereas C͞EBP␤ null littermates did not develop any tumors ( Fig. 1 c and d ). Because both MNNG-and DMBA-initiated mice were treated with TPA, it was possible that the inability of C͞EBP␤-null mice to develop tumors resulted from a defective response to TPA or to an initiation͞promotion protocol. Therefore, we used a complete carcinogenesis protocol in which wild-type and C͞EBP␤-null mice were treated weekly with DMBA. All of the wild-type mice developed papillomas with an average of 12 papillomas/mouse whereas C͞EBP␤ mutant mice were again completely resistant to carcinogenesis ( Fig. 1 e and f ) . We also observed that C͞EBP␤-null mice were refractory to DMBA-initiation followed by promotion with the non-phorbol ester tumor promoter mirex (data not shown). Thus, C͞EBP␤ nullizygous mice are fully resistant to tumorigenesis induced by a variety of carcinogens, tumor promoters, and carcinogenesis protocols that, in normal mice, cause tumors that contain mutant oncogenic Ha-ras or Ki-ras (25, (27) (28) (29) 41) . These results suggest that C͞EBP␤ is an essential downstream mediator of oncogenic Ras tumorigenesis.
The lack of tumor development in carcinogen-treated C͞EBP␤-null mice could be caused by apoptosis of C͞EBP␤-deficient keratinocytes that have acquired oncogenic Ha-ras lesions. To examine this possibility, we treated mice with DMBA and scored the number of apoptotic keratinocytes in C͞EBP␤-null and wildtype epidermis by using the cytological parameters described in Methods. Compared with wild-type mice, C͞EBP␤-null mice exhibited a 17-fold increase in the number of basal apoptotic keratinocytes ( Table 2 ), indicating that C͞EBP␤ functions as a survival factor in DMBA͞Ras-induced oncogenesis. Similar fold increases in apoptotic cells were observed by using terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) staining (data not shown). To determine whether C͞EBP␤-null mice also display increased apoptosis in response to UVB irradiation, a potent inducer of apoptosis and DNA damage, wild-type and C͞EBP␤-null mice were irradiated with UVB doses of 50, 200, and 500 mJ/cm 2 . Although all UVB doses increased the number of apoptotic epidermal keratinocytes, there was no difference between wild-type and mutant mice (data not shown). These results show that the enhanced apoptosis in DMBA-treated C͞EBP␤-null mice is stimulus specific and that DNA damage alone is not sufficient to elicit increases in apoptosis in epidermal keratinocytes of C͞EBP␤-null mice. To provide additional evidence for a relationship between Ras and C͞EBP␤ in skin tumorigenesis, we crossed C͞EBP␤-null mice with Tg.AC transgenic mice. Tg.AC mice contain a v-Ha-ras transgene under the control of a partial -globin promoter and are susceptible to skin tumor development in the absence of carcinogen exposure (31) . Tumorigenesis in Tg.AC mice does require a promoting stimulus, such as wounding, or treatment with a tumor promoter. As shown in Fig. 2a , TPA-treated C͞EBP␤-deficient mice carrying the v-Ha-ras transgene developed Ϸ65% fewer skin tumors than C͞EBP␤ ϩ/ϩ transgene-positive mice, and the tumor size (Fig. 2b C͞EBP␤ Activation by Ha-ras Signaling in Keratinocytes. To ascertain whether oncogenic Ha-ras signaling can stimulate C͞EBP␤ activity in epidermal keratinocytes, we transfected BALB͞MK2 keratinocytes with C͞EBP␤ and͞or Ha-ras(12V) and a luciferase reporter gene fused to different lengths of the C͞EBP-dependent my- Mice were treated with a single application or thrice weekly for 1 month with 5 nmol TPA͞200 l acetone or with acetone alone. BrdUrd labeling was conducted by a single-dose i.p. injection of BrdUrd 18 h after the last TPA treatment; 1 h later the animals were euthanized, and immunochemical staining of BrdUrd-positive cells was performed (14, 16) . Data are expressed as the mean Ϯ SD from at least three mice. Each value for wild-type mice and similarly treated C͞EBP␤-null mice within each category was not significantly different (P Ͼ 0.05) as determined by the Student's t test. Mice (three per group) were treated with a single application of 400 nmol DMBA͞200 l acetone or acetone alone. More than 4,000 basal keratinocytes were counted for each individual mouse. Data are expressed as mean Ϯ SD. *, Significantly different from acetone-treated group (P Ͻ 0.01) as determined by Student's t test. †, Significantly different from wild-type DMBA-treated group (P Ͻ 0.01) as determined by Student's t test. elomonocytic growth factor (MGF) promoter (16, 42) . pMGF-40 contains a 40-bp portion of the MGF promoter that lacks C͞EBP sites, whereas pMGF-82 contains an additional 42-bp region of the promoter harboring two C͞EBP-binding sites. Cotransfection of Ha-ras(12V) and C͞EBP␤ resulted in 30-and 80-fold increases, respectively, in pMGF-82 reporter activity over that observed with C͞EBP␤ or Ha-ras(12V) alone (Fig. 3a) . In contrast, cotransfection of Ha-ras(12V) and C͞EBP␤ caused only a 5-fold increase in transcription from the MGF-40 promoter, demonstrating that C͞EBP binding sites are required for the synergistic response. Similar results were obtained by using a minimal albumin promoter with four tandem C͞EBP sites [(DE1) 4 -Alb-luc] (Fig. 3b and ref.  43 ). Western blot analysis of cell lysates from BALB͞MK2 cells cotransfected with C͞EBP␤ and Ha-ras(12V) demonstrated that the observed synergistic effect on C͞EBP-responsive promoterreporter activity is not caused by increased Ha-ras(12V) or C͞EBP␤ expression (Fig. 3c) .
Cotransfection of Ha-ras(12V) with a truncated form of C͞EBP␤ (LIP) that lacks the N-terminal activation domain but retains the bZIP DNA-binding and leucine zipper domain (44) did not increase the activity of the pMGF-82 reporter (Fig. 4a) . In fact, LIP inhibited the activation of wild-type C͞EBP␤ by Ha-ras(12V) by Ϸ50%, which is consistent with its known role as a dominant negative inhibitor of C͞EBP␤ (44) (Fig. 4a) . Studies have identified an ERK1͞2 phosphorylation site (T188) in C͞EBP␤, and substituting T188 with alanine diminished Ras activation of C͞EBP␤ (22) . Therefore, we tested the Ras-responsiveness of a C͞EBP␤ mutant containing the T188A substitution. Oncogenic Ha-rasinduced stimulation of C͞EBP␤ activity was abolished in this mutant (Fig. 4b) . Thus, an oncogenic Ha-ras pathway can activate C͞EBP␤ in keratinocytes, and this activation depends on T188 of C͞EBP␤.
To determine whether endogenous C͞EBP␤ can mediate Ras signaling, we transfected primary keratinocytes isolated from C͞EBP␤-nullizygous and wild-type mice with oncogenic Ha-ras and the C͞EBP promoter-reporter constructs. Transfection of Ha-ras(12V) into wild-type keratinocytes resulted in a 30-fold increase in pMGF-82 reporter activity whereas in C͞EBP␤-nullizygous keratinocytes Ha-ras(12V) caused less than a 4-fold increase (Fig. 5 a and b) . The Ras-induced increase in promoter activity required C͞EBP binding sites (Fig. 5a) . Similar results were obtained with the (DE1) 4 -Alb-luc reporter (data not shown). Ectopic expression of C͞EBP␤ in C͞EBP␤-null keratinocytes restored responsiveness to oncogenic Ras (Fig. 5a) . Thus, endogenous C͞EBP␤ is a downstream mediator of oncogenic Ha-ras signaling in primary keratinocytes.
C͞EBP␤ Augments Ras-Induced Transformation of NIH 3T3 Cells.
The NIH 3T3 focus assay has been widely used to identify pathways and genes that cooperate with Ras to induce transformation (33) . To examine the role of C͞EBP␤ in NIH 3T3 transformation, we first confirmed that oncogenic Ras could stimulate C͞EBP␤ to activate a C͞EBP-responsive promoter-reporter in NIH 3T3 cells (ref. 22 and data not shown). Next we examined whether C͞EBP␤ has the capacity to transform cells and͞or cooperate with oncogenic Ha-ras to increase its transforming potential in the NIH 3T3 focus formation assay. Transfection of C͞EBP␤ alone did not induce NIH 3T3 transformation ( Table 3) , showing that this transcription factor does not possess intrinsic transforming activity. Cotransfection of 5 or 10 ng of C͞EBP␤ enhanced the transformation potential of oncogenic Ha-ras(12V), producing a Ϸ1.3-and 1.7-fold increase, respectively, in the number of transformed foci compared with Ha-ras(12V) alone (Table 3) . Paradoxically, cotransfection of 50 ng of C͞EBP␤ with Ha-ras(12V) inhibited transformation by 20%, BALB͞MK2 keratinocytes were transfected with pcDNA3-C͞EBP␤ (0.5 g) and͞or pcDNA3-Ha-ras(12V) (0.5 g) and 1.0 g of the specified C͞EBP-dependent promoter͞reporter as described in the text. Luciferase activity is expressed as fluorescent units per g of protein, and each value represents the mean Ϯ SD of triplicate dishes per treatment. Similar results were obtained from two repeat experiments. Inclusion of pSV-␤-galactosidase and subsequent normalization of luciferase to ␤-galactosidase activity produced similar results to those normalized to protein levels. (c) BALB͞MK2 keratinocytes were transfected with Ha-ras(12V) and͞or C͞EBP␤, and 48 h later, lysates were prepared and Western analysis was conducted. Fig. 4 . Activation of C͞EBP␤ by oncogenic Ha-ras involves a T188 and requires the presence of the C͞EBP␤ transactivation domain. BALB͞MK2 keratinocytes were transfected with 1.0 g of the promoter͞reporter MGF82-luc and 0.5 g of one or more of the specified vectors. The experimental procedures were carried out as described in the legend to Fig. 3 . Each value represents the mean Ϯ SD of triplicate dishes per treatment. Similar results were obtained from two repeat experiments. Inclusion of pSV-␤-galactosidase and subsequent normalization of luciferase to ␤-galactosidase activity produced similar results to those normalized to protein levels.
suggesting that the enhancing effect of C͞EBP␤ is not only saturable, but that high levels of C͞EBP␤ can inhibit ras transformation, perhaps because of a nonspecific effect of transfecting too high a level of C͞EBP␤. Importantly, we observed that cotransfection of 10 ng LIP or 10 ng C͞EBP␤ T188A inhibited Ha-ras(12V)-induced transformation, indicating an important role for endogenous C͞EBP␤ in ras-induced transformation of NIH 3T3 cells. C͞EBP␤ also enhanced the transforming potential of oncogenic Raf, lending further support for a Ras-Raf-ERK-C͞EBP␤ pathway. In contrast to C͞EBP␤, neither C͞EBP␣ or C͞EBP␦ enhanced the transforming activity of oncogenic Ha-ras(12V) ( Table 3) . Thus, not all C͞EBP family members are capable of augmenting Ras transformation.
Discussion
We have identified C͞EBP␤ as a critical gene in two established in vivo models of Ras-mediated epithelial tumorigenesis as well as in Ras-induced transformation of NIH 3T3 fibroblasts. C͞EBP␤ was found to be essential for skin tumorigenesis induced by a variety of carcinogens that are known to cause the mutational activation of Ha-ras and K-ras. Moreover, C͞EBP␤ deficiency in oncogenic v-Ha-ras transgenic mice inhibited v-Haras-induced tumorigenesis by 60%. Substitution of C͞EBP␤ T188 with alanine, which disrupts an ERK1͞2 phosphorylation site, blocked the ability of Ras to stimulate C͞EBP␤ transactivation function and also inhibited Ras-induced NIH 3T3 transformation. Although our studies cannot rule out the existence of a Ras-independent pathway responsible for the observed responses in the C͞EBP␤-deficient mice, our collective results do implicate C͞EBP␤ as a critical component of a Ras-dependent tumorigenesis͞transformation pathway. Future studies using of C͞EBP␤ Ϫ/Ϫ MEFs may provide further insight into the exact role of C͞EBP␤ in Ras-induced transformation and apoptosis.
Depending on the cellular context, strength of signal, and pathways engaged, oncogenic Ras can regulate cell proliferation, differentiation, senescence, apoptosis, or survival (3, 45, 46) . Rasinduced apoptosis is suppressed by its activation of pro-survival pathways involving NF-B (2) or Rac GTPase (46); if these pathways are blocked, apoptosis results. Moreover, in PC-12 cells the MEK͞ERK pathway promotes cell survival (47) . We have observed that C͞EBP␤-null mice display a 17-fold increase in the number of apoptotic keratinocytes in DMBA-treated epidermis compared with similarly treated wild-type epidermis. Studies in mouse epidermis have indicated that 0.1-5% of Ha-ras genes sustain a codon-61 mutation within 1-3 days of topical carcinogen application (48) . The observed increase in apoptotic cells in DMBA-treated C͞EBP␤-deficient epidermis is consistent with a survival͞antiapoptotic role for C͞EBP␤ in oncogenic Rasexpressing cells. Previously we demonstrated that C͞EBP␤ positively regulates the program of squamous differentiation in the epidermis and in isolated keratinocytes (16) . Therefore, we suggest that in normal keratinocytes C͞EBP␤ regulates differentiation as well as survival, which is required to complete the differentiation program. However, in the presence of oncogenic Ha-ras the C͞EBP␤ prosurvival response may predominate over the differentiation pathway and clonal expansion occurs, ultimately resulting in tumor formation. When the C͞EBP␤ prosurvival signaling pathway is deleted as in the C͞EBP␤-deficient mice, cells containing oncogenic Ras undergo apoptosis and tumorigenesis is blocked.
In addition to Ras, there is evidence for additional DMBA target genes that cooperate with oncogenic Ras to induce skin tumorigenesis, and it is conceivable that C͞EBP␤ is also a component of non-ras oncogenic circuitry (49) . Such a notion is consistent with our observation that C͞EBP␤ deficiency in the v-Ha-ras transgenic mice did not result in the complete inhibition of tumorigenesis. Alternatively, it is possible that high levels of expression of v-Ha-ras transgene in Tg.AC epidermal keratinocytes and͞or the expression of the transgene within a different subpopulation of keratinocytes could account for the differences between the degree of inhibition of tumorigenesis in v-Ha-ras and carcinogen-treated C͞EBP␤-deficient mice. C͞EBP␤-null keratinocytes could also have a defective DNA repair mechanism that contributes to the elevated levels of DMBA-induced apoptosis. However, such a mechanism would not involve all forms DNA damage, as we did not observe differences in UVB-induced apoptosis in wild-type versus . Endogenous C͞EBP␤ is a downstream mediator of oncogenic Ha-ras signaling in keratinocytes. Primary keratinocytes were isolated from C͞EBP␤ Ϫ/Ϫ or C͞EBP␤ ϩ/ϩ newborn littermates (2-3 days old) and cultured as described (14, 16) . Primary keratinocytes were transfected with the specified vector (0.5 g each) and 1.0 g of the C͞EBP-dependent promoter͞reporter vector and were processed as described in the legend to C͞EBP␤-null keratinocytes. Moreover, because both UVBinduced pyrimidine dimers and DMBA bulky adducts are repaired by the same nucleotide excision repair mechanism, it is unlikely that defects in nucleotide excision repair account for the elevated level of DMBA-induced apoptosis in C͞EBP␤-null mice. MNNGinduced DNA damage is repaired by a base excision repair mechanism, suggesting that activation of ras and not altered DNA repair is the common link between the two carcinogens. Collectively, our results tend to support a role for C͞EBP␤ in the survival of oncogenic Ha-ras cells.
The complete inhibition of tumorigenesis in carcinogen-treated C͞EBP␤-deficient mice is striking and is, to our knowledge, the most profound inhibitory effect of a single gene deletion on skin tumorigenesis reported to date. The potent effect of C͞EBP␤ in an experimental mouse model raises the question of whether C͞EBP␤ plays a similar role in human cancers. Interestingly, C͞EBP␤ levels are strongly increased in human colorectal tumors (50) and are also associated with human ovarian epithelial tumor progression (51) . Thus, the induction of C͞EBP␤ may be an important event in the development epithelial tumors, perhaps by providing an essential antiapoptotic signal.
Recent studies have implicated another C͞EBP family member, C͞EBP␣, in myeloid leukemogenesis. However, in contrast to C͞EBP␤, C͞EBP␣ functions as a tumor suppressor by promoting granulocytic differentiation and growth arrest. Thus, C͞EBP␣ inactivation by mutation (52) or by its association with the oncoprotein AML-1-ETO (53, 54) contributes to myeloid leukemogenesis by maintaining cells in an extended proliferative state. It is notable that, despite their structural relatedness, C͞EBP␤ and C͞EBP␣ apparently play very different roles in transformed cells and have opposite effects on tumorigenesis.
Although further studies are required to discern the downstream pathways and genes through which C͞EBP␤ regulates tumor development, our study reveals a function for C͞EBP␤ as a critical component of the tumorigenesis pathway initiated by activated Ras. C͞EBP␤ may therefore represent an attractive target for antineoplastic pharmacological agents.
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